Earnings ·
Reports Q2 net loss of $6.4M and sales decline to $35.8M as PetMed stabilizes operations
PETSPetmed Express Inc
PetMed Express reported a net loss of $6.4 million, or $(0.31) per diluted share, for the second quarter ended September 30, 2026, compared to a loss of $8.5 million in the prior year period. Net sales decreased 19.4% to $35.8 million from $44.4 million, driven by lower prescription medication sales and higher consumer promotional usage. Adjusted EBITDA widened to $(3.6) million from $(2.3) million. The company cited lower general and administrative expenses and advertising costs as key drivers of the improved net loss performance, partially offset by unfavorable product mix shifts and lower manufacturer rebates. PetMed Express operates in the direct-to-consumer pet healthcare sector, providing pharmaceuticals and supplements through its online pharmacy brands.